[go: up one dir, main page]

NO952194D0 - Spirofuranone derivatives and their use in the treatment of neurodegenerative diseases - Google Patents

Spirofuranone derivatives and their use in the treatment of neurodegenerative diseases

Info

Publication number
NO952194D0
NO952194D0 NO952194A NO952194A NO952194D0 NO 952194 D0 NO952194 D0 NO 952194D0 NO 952194 A NO952194 A NO 952194A NO 952194 A NO952194 A NO 952194A NO 952194 D0 NO952194 D0 NO 952194D0
Authority
NO
Norway
Prior art keywords
spirofuranone
derivatives
treatment
neurodegenerative diseases
neurodegenerative
Prior art date
Application number
NO952194A
Other languages
Norwegian (no)
Other versions
NO952194L (en
Inventor
Alexander Kover
Iii James Loch
George Mullen
Edwin Shen-Chou Wu
Original Assignee
Fisons Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929225498A external-priority patent/GB9225498D0/en
Priority claimed from GB929225497A external-priority patent/GB9225497D0/en
Priority claimed from GB939316531A external-priority patent/GB9316531D0/en
Application filed by Fisons Corp filed Critical Fisons Corp
Publication of NO952194D0 publication Critical patent/NO952194D0/en
Publication of NO952194L publication Critical patent/NO952194L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO952194A 1992-12-05 1995-06-02 Spirofuranone derivatives and their use in the treatment of neurodegenerative diseases NO952194L (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB929225498A GB9225498D0 (en) 1992-12-05 1992-12-05 Pharmacologically active compounds
GB929225497A GB9225497D0 (en) 1992-12-05 1992-12-05 Pharmacologically active compounds
GB939316531A GB9316531D0 (en) 1993-08-10 1993-08-10 Pharmacologically active compounds
PCT/GB1993/002500 WO1994013678A1 (en) 1992-12-05 1993-12-06 Spirofuranone derivatives and their use in the treatment of neurodegenerative disorders

Publications (2)

Publication Number Publication Date
NO952194D0 true NO952194D0 (en) 1995-06-02
NO952194L NO952194L (en) 1995-06-02

Family

ID=27266497

Family Applications (1)

Application Number Title Priority Date Filing Date
NO952194A NO952194L (en) 1992-12-05 1995-06-02 Spirofuranone derivatives and their use in the treatment of neurodegenerative diseases

Country Status (10)

Country Link
EP (1) EP0672046A1 (en)
JP (1) JPH08503955A (en)
KR (1) KR950704322A (en)
AU (1) AU5655394A (en)
CA (1) CA2150947A1 (en)
FI (1) FI952733A0 (en)
IL (1) IL107881A0 (en)
MX (1) MX9307679A (en)
NO (1) NO952194L (en)
WO (1) WO1994013678A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU741566B2 (en) * 1997-01-27 2001-12-06 Warner-Lambert Company Single pot process for producing (Z)-azabicyclo oxime ethers
TWI243173B (en) 1999-11-17 2005-11-11 Akzo Nobel Nv Spiro[2H-1-benzopyran-2,4'-piperidine] derivatives
DE602004010186T2 (en) 2004-01-08 2008-07-03 F. Hoffmann-La Roche Ag DIAZASPIROPIPERIDINE DERIVATIVES AS INHIBITORS OF GLYCINTRANSPORTER 1 AND GLYCINTRANSPORTER 2

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075317A (en) * 1989-06-21 1991-12-24 Fisons Corporation Spirofurane derivatives
JPH03153690A (en) * 1989-11-10 1991-07-01 Yamanouchi Pharmaceut Co Ltd Heterocyclic spiro derivative and production thereof
IE914238A1 (en) * 1990-12-19 1992-07-01 Fisons Corp Novel spirofurane derivatives

Also Published As

Publication number Publication date
JPH08503955A (en) 1996-04-30
CA2150947A1 (en) 1994-06-23
KR950704322A (en) 1995-11-17
WO1994013678A1 (en) 1994-06-23
FI952733A7 (en) 1995-06-05
FI952733A0 (en) 1995-06-05
AU5655394A (en) 1994-07-04
IL107881A0 (en) 1994-04-12
MX9307679A (en) 1994-06-30
EP0672046A1 (en) 1995-09-20
NO952194L (en) 1995-06-02

Similar Documents

Publication Publication Date Title
NO994014D0 (en) Arylsulfonamides and analogs thereof and their use in the treatment of neurodegenerative diseases
BR9406209A (en) Heterocyclic derivatives in the treatment of ischemia and related diseases
NO942283L (en) Pyrophophorbids and their use in photodynamic therapy
NO972972D0 (en) Compositions for the treatment of dermatological disorders and methods for their use
FI944549A7 (en) Compounds useful in the treatment of allergic and inflammatory diseases
FI953838L (en) Imidazopyridines and their use in the treatment of gastrointestinal diseases
NO992641D0 (en) Mixtures and Methods for the Treatment or Prevention of Inflammatory Diseases
AU3959193A (en) Heterocyclic compounds and their use in the treatment of type II-diabetes
NO20001412D0 (en) Compositions and Methods in the Treatment of Respiratory Disorders
NO984836L (en) Substituted benzylamines and their use in the treatment of depression
FI955786A0 (en) Use of natural products and similar compounds in the treatment of cardiovascular diseases
FI924475A7 (en) Use of trinitrobenzenes or carminic acid in the treatment of cancer and viral diseases
FI954138L (en) Hydroxymethylfurazancarboxylic acid derivatives and their use in the treatment of cardiovascular diseases
DE69120933D1 (en) Topical application of glycosaminoglycans for the prevention and treatment of cervical or vaginal diseases
NO934311L (en) alpha, omega-diarylalkane derivatives, their preparation and use in the treatment of circulatory disorders and psychoses
NO985974D0 (en) Piperidinedacetic acid derivatives and their use in the treatment of thrombosis diseases
AU4787593A (en) Heterocyclic derivatives useful in the treatment of cardiovascular diseases
FI956353L (en) Pharmaceutical preparations and their use, especially in the treatment of neurodegenerative diseases
IL115505A0 (en) Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
NO952194D0 (en) Spirofuranone derivatives and their use in the treatment of neurodegenerative diseases
DE59306085D1 (en) HAIR AND BODY TREATMENT
ZA908490B (en) Use of arylalkylamides in the treatment of neurodegenerative diseases
NO942686D0 (en) Use of 3-arylindole and 3-arylindazole derivatives in the treatment of psychoses
NO922340D0 (en) FR, AND PROCEDURE FOR AA OPTIMIZE THE EFFECT OF PIGMENTS IN FOR SALMONIDES
FI973259A7 (en) Use of LCK-SH2-specific compounds in the treatment of autoimmune diseases and tissue transplant rejection